Division of Integra LifeSciences Holdings Corp.
Latest From IsoTis SA
Now among the most promising of an emerging group of second-generation transcatheter aortic valve implantation (TAVI) companies, Symetis didn’t start out that way. It began as a cell therapy company, but its initial technology failed. On the verge of running out of money, CEO Jacques Essinger, PhD, engineered a change of direction that ultimately turned Symetis into a TAVI company with the kinds of advantages that may provide it with a competitive advantage.
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- Modex Therapeutics SA
- Modex Therapeutics Ltd.
- Matrix Medical
- Western Europe
- Parent & Subsidiaries
- Integra LifeSciences Holdings Corp.
- Senior Management
Robert J Morocco, CFO
Alan Donze, VP, Sales
Kathryn Liljestrand, VP, Mktg.
- Contact Info
Phone: (41) 21 620 60 00
1 Rue de Sebeillon
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.